Key findings
- Cumulative SARS-CoV-2 seroincidence was 69% among 224 adults tested in July 2021 and 84% among the 114 re-tested in April 2022, mostly before vaccination.
- About half of infections showed evidence of neutralising antibodies.
- In the peak weeks of viral activity, excess mortality was 22% at ages 30 to 69 and 70% at ages over 70.
- Across 2020 to 2022, deaths at ages 30 and over were about 6% above the expected number.
About this study
Background
HEAL-SL calculates excess mortality by comparing all-cause mortality before and during infectious disease outbreaks. SARS-CoV-2 is among the priority pathogens of the Healthy City Study, the HEAL-SL dried blood spot serosurvey.
What was done
In July 2021, dried blood spots were collected from 4,160 adults in 41 randomly selected HEAL-SL sampling units in Bo District. Samples from 224 randomly selected adults were tested for SARS-CoV-2 antibodies, and 114 of the 224 were sampled again in April 2022. The serology was paired with nationally representative HEAL-SL mortality data and selected death registration data.
Results
Cumulative seroincidence was 69% among the 224 adults in July 2021 and 84% among the 114 re-tested in April 2022, mostly before vaccination. About half of infections showed evidence of neutralising antibodies. Excess death rates were low and concentrated at older ages. In the peak weeks of viral activity, excess mortality was 22% at ages 30 to 69 and 70% at ages over 70. Across 2020 to 2022, deaths at ages 30 and over were about 6% above expected.
Status
Completed. The study was published in PLOS Global Public Health on 10 September 2024.
Source: Osman et al., PLOS Global Public Health, 2024.
Outputs
High SARS-CoV-2 seroincidence but low excess COVID mortality in Sierra Leone in 2020-2022
PublishedJournal article · September 2024Osman A, et al. PLOS Global Public Health 2024;4(9):e0003411.
Study team
- Partners
- Njala University
- Ministry of Health, Government of Sierra Leone
- National Civil Registration Authority
- Centre for Global Health Research, University of Toronto
- Bill & Melinda Gates Foundation (funder)
- Canadian Institutes of Health Research (funder)
- Canadian Immunity Task Force (funder)
- Unity Health Toronto Foundation (funder)
- Study leads
- Prof. Rashid Ansumana — Njala University
- Prof. Prabhat Jha — University of Oxford